The U.S. market for bacterial conjunctivitis drugs is highly fragmented in nature, with the presence of a large number of players operating in it, states a research study by Transparency Market Research. The number of new entrants is projected to rise substantially throughout the forecast period, resulting in a stiff competition among the leading players. F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Valeant Pharmaceuticals Int. Inc., Bayer AG are some of the leading players operating in the U.S. bacterial conjunctivitis drugs market. These players are emphasizing on collaborations and development of new products in order to enhance their presence and attain a leading position in the market. However, with the rising research and development activities and the improving production capacities, the market is likely to witness a downward trend in the near future.
According to the research study by Transparency Market Research, the U.S. market for bacterial conjunctivitis drugs is anticipated to reach a value of US$439.8 mn by the end of 2024 from US$473.3 mn in 2013. As a result, the market is expected to register a sluggish growth throughout the forecast period.
Patent Expiry of Top Brands to Curtail Growth in U.S.
At present, the U.S. market for bacterial conjunctivitis drugs market is likely to witness diminishing growth, owing to the patent expiry of top branded formulations. The leading drug manufacturers in the market are anticipated to lose their share in the next few years. The rising competition among the players and the increasing preference of consumers towards herbal medications are some of the major factors that are estimated to hamper the growth of the U.S. bacterial conjunctivitis drugs market throughout the forecast period.
Macrolides, fluoroquinolones, and aminoglycosides are considered as the major classes of drugs that are used widely for curing bacterial conjunctivitis drugs market in the U.S. A significant demand for topical fluoroquinolones is expected among the leading drugs throughout the forecast period. However, the share of this segment is predicted to decrease, due to the upcoming patent expirations of the bestselling drugs in this class, including Moxeza, Vigamox, and Zymaxid. Nevertheless, the development of new effective drugs is expected to enhance the growth of the market throughout the forecast period.
Development of New Products to Encourage Growth
The increasing incidence of ophthalmic bacterial infection and the rising cases of bacterial conjunctivitis infection among different age groups are the key factors that are estimated to encourage the growth of the U.S. bacterial conjunctivitis drugs market in the next few years. In addition, the rising focus of the leading players on the production and designing of combination drugs is likely to accelerate the growth of the overall market in the next few years.
On the flip side, the increasing number of patent expirations is anticipated to restrict the growth of the bacterial conjunctivitis drugs market in the U.S. over the forecast period. In addition, the rising multi-drug resistant bacterial strains is anticipated to curtail the market’s growth in the coming years. As a result, the key players in the market are predicted to witness several challenges in the near future. Nevertheless, the increasing focus on the implementation of product development partnerships business models is likely to generate promising growth opportunities for key players operating in the bacterial conjunctivitis drugs market in the U.S.
This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Bacterial Conjunctivitis Drugs Market (Drug Class - Fluoroquinolones (Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, Besifloxacin), Aminoglycosides (Tobramycin, Gentamycin), Macrolides (Erythromycin, Azithromycin)) - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 - 2024.”
The U.S. bacterial conjunctivitis drugs market has been segmented as below:
U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
U.S. Bacterial Conjunctivitis Drugs Market, by Pipeline Assessment
- Vancomycin Ophthalmic Ointment
- Early Stage (Phase I and Phase II trials) – Tabular Representation
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC